The global epidemic of drug-resistant tuberculosis is a catastrophic example of how antimicrobial resistance is undermining the public health gains made possible by combination drug therapy. Recent evidence points to unappreciated bacterial factors that accelerate the emergence of drug resistance. In a genome-wide association study of Mycobacterium tuberculosis isolates from China, we find mutations in the gene encoding the transcription factor prpR enriched in drug-resistant strains. prpR mutations confer conditional drug tolerance to three of the most effective classes of antibiotics by altering propionyl-CoA metabolism. prpR-mediated drug tolerance is carbon-source dependent, and while readily detectable during infection of human macrophages, is not captured by standard susceptibility testing. These data define a previously unrecognized and clinically prevalent class of M. tuberculosis variants that undermine antibiotic efficacy and drive drug resistance.
T he incidence of multidrug-resistant tuberculosis (MDR-TB, a term that denotes combined resistance to the potent first-line drugs isoniazid and rifampin) has increased to an estimated 490,000 cases annually even though the multidrug regimens used to treat TB are specifically designed to suppress the emergence of drug resistance 1 . The recognized risk factors for acquired drug resistance and treatment failure more generally are the use of inappropriate antibiotic regimens 2 and patient non-adherence 3, 4 . However, even when patients are treated in clinical trial settings, with carefully administered antibiotic regimens that reflect the best available phenotypic and genotypic predictions of drug susceptibility, failures still occur in 5-10% of TB cases [5] [6] [7] .
In most bacterial pathogens, including Mycobacterium tuberculosis, antibiotic resistance is defined through growth-based resistance assays or their genetic proxies. However, these assays fail to capture more complex alterations in drug susceptibility that may contribute to the emergence of de novo drug resistance and treatment failure even in the absence of resistance as it is conventionally measured. Recent in vitro evolution studies in Escherichia coli have identified mutations that slow bacterial killing during antibiotic treatment without an increase in the minimum inhibitory concentration 8, 9 . Alterations in bacterial killing can be broadly placed into two categories that can be distinguished by their kill kinetics: population-wide tolerance, where all cells are more refractory to killing, or increased production of rare, highly tolerant persister cells, where the bulk of the population remains fully susceptible 10 . Persister cells are thought to be protected from killing by decreased dependence on antibiotic targets essential for growth-related processes 11 .
Clinical isolates of the pathogens Pseudomonas aeruginosa and Candida albicans with increased production of persister cells have been identified, suggesting that this phenotype can emerge during treatment 12, 13 . In M. tuberculosis, persister cells have been postulated to contribute to the long duration of antibiotic therapy required to treat infection 14, 15 . In vitro studies in M. tuberculosis and other prokaryotes have also identified forms of drug tolerance including blunted drug efficacy due to population-wide slow-growth states in specific conditions 16, 17 , and conditional drug efflux 18 . Furthermore, bacterial mutants that are specifically drug tolerant in vivo but drug susceptible in vitro have been isolated in laboratory studies; however, the mechanism(s) of in vivo drug tolerance has not been defined 19 . Importantly, studies in E. coli have shown that persistence and tolerance mutations can accelerate the subsequent emergence of drug resistance 20, 21 .
In an effort to identify variants altering antibiotic susceptibility in natural populations of M. tuberculosis, we undertook a genomewide association study of clinical isolates, correlating mutations with drug resistance. We identify several loci associated with resistance and demonstrate that variants in the gene encoding the bacterial transcription factor prpR confer conditional multidrug tolerance.
Results

Genetic variants associated with drug-resistant TB in China.
To identify clinically relevant bacterial variants altering antibiotic efficacy in M. tuberculosis, we performed a bacterial genomewide association analysis in strains isolated from TB is patients. Antibiotic tolerance is not measured clinically but may serve as a stepping stone to the evolution of resistance 21 . We therefore Articles NATuRe MICRobIology reasoned that associations with drug resistance should also capture tolerance mutations that increase the probability that a strain will subsequently develop resistance. To perform this analysis, we leveraged a strain collection assembled during the 2007 national survey of drug-resistant TB in China 22 . In this study, ~4,000 strains were collected from across China and resistance was measured for 6 firstand second-line antibiotics. A subset of 549 strains was selected for whole-genome sequencing including all isoniazid-resistant and MDR strains and a geographically matched set of drug-susceptible strains ( Fig. 1a and Supplementary Table 1 ).
To define the phylogenetic structure of M. tuberculosis in China, we performed whole-genome sequencing and identified single nucleotide polymorphisms (SNPs) by comparing each strain with the laboratory strain H37Rv (Supplementary Table 1 ). The phylogenetic structure of M. tuberculosis in our cohort is broadly consistent with published phylogenies 23, 24 (Fig. 1b and Supplementary Fig. 1 ). As expected, drug-resistant M. tuberculosis in China is dominated by lineage 2 strains, accounting for 81% of drug-resistant isolates, the majority of which are part of sublineage L2.3 (also known as 'modern' Beijing). Chinese lineage 4 strains comprise 18% of drugresistant isolates and form three distinct groups, which are generally restricted to China, as assessed by the distribution of publicly available M. tuberculosis genomes from other geographic locations ( Fig. 1b and Supplementary Table 2 ). A genetic distance-based cluster analysis demonstrated that ~90% of isoniazid-resistant isolates in this sample reflect independent acquisitions of drug resistance ( Supplementary Fig. 2 ). As the existing collections of sequenced drug-resistant M. tuberculosis are frequently dominated by epidemic clones 25, 26 , this is a uniquely robust cohort for the identification of bacterial factors driving the acquisition of drug resistance.
To detect genetic associations in the context of the completely clonal M. tuberculosis population structure, we identified mutations occurring in isoniazid-resistant isolates more often than would be expected by chance based on phylogenetic convergence at a gene-wide level 27 , using an algorithm that we termed phyOverlap. Isoniazid resistance typically arises first in the progression to MDR 28 and second-line drugs are used only in the context of pre-existing MDR, leading to programmatic linkage among drugresistance phenotypes ( Supplementary Table 3 ). Thus, by performing an association analysis with isoniazid resistance, we expected to capture mutations altering the efficacy of multiple clinically utilized antibiotics.
From this analysis, we identified 13 genes and inter-genic regions that are significantly (q < 0.05) associated with isoniazid resistance ( Fig. 1c and Supplementary Table 4 ). The associations with the highest significance included the well-established isoniazid-resistancedetermining genes and regulatory regions (katG, inhA promoter and ahpC promoter mutations). As expected, known resistancedetermining and compensatory mutations for other first-and second-line antibiotics are also significantly associated with isoniazid resistance, reflecting the multiple resistances present in many MDR isolates. Among these high-confidence associations, an association was identified with prpR or Rv1129c (q = 0.018) for which there is no known mechanistic basis for the coincidence of mutations and drug resistance.
Convergence-based phyOverlap analysis of two additional publicly available data sets from a Chinese cohort 29 and a mixed UK/African cohort 30 (Supplementary Tables 5 and 6) , as well as a meta-analysis of all three data sets, independently supported the association between prpR and isoniazid resistance (Fig. 1d ). The meta-analysis also identified several additional known drug-resistant-associated loci, including ethA, gid and the eis promoter. The most significant association in this analysis for which a mechanistic basis is unknown is Rv2752c, encoding a potentially bifunctional protein that has been demonstrated to have both RNase J-like activity and beta-lactamase activity 31, 32 , and which frequently contains nonsense or INDEL mutations presumably abolishing function. Four additional genes were identified that failed to meet the corrected genome-wide significance threshold; however, they were nested within four known resistance-associated loci (Fig. 1d ). These genes include helY (Rv2092c) and dnaA, both implicated in DNA replication and repair; Rv3402c, which encodes a conserved hypothetical protein; and Rv1830, which encodes another putative transcription factor (Fig. 1d ).
The distribution of prpR mutations in global Mycobacterium tuberculosis populations. Although prpR mutants are strongly associated with drug resistance in our analysis, only a single previous genomic study, also performed using Chinese isolates, has implicated prpR in resistance 29 . To gain a broader context for the incidence of prpR mutation among clinical isolates, we assessed the frequency of prpR mutants within the three data sets included in Fig. 1d as well as in three additional large genomic data sets from other regions of the world [33] [34] [35] . In these three additional global data sets, we also performed targeted genetic analysis to measure the association between prpR mutations and mutations in katG and the inhA promoter regions as a proxy for isoniazid resistance (Table 1) . Overall, the occurrence of prpR mutants in samples derived from outside China is markedly lower, representing just 2-3% of isolates overall as compared with 8-10% in Chinese isolates. In all data sets except for Casali et al. 34 from Russia, the uncorrected frequency of prpR mutations is higher in the drugresistant isolates than in drug-susceptible isolates. After correcting for phylogenetic structure as described above, prpR mutations are significantly associated with drug resistance in all data sets except the Malawian cohort, which has relatively little drug resistance overall. The discrepancies in the Russian and Malawian cohorts probably reflect the effects of clonal drug-resistant outbreaks, which strongly skew the frequency estimates.
Functional characterization of clinical prpR mutations. prpR has no previously known role in resistance to any antibiotic, although in an observational study examining the treatment of a single MDR patient over time, a prpR mutant was driven to near fixation while the patient was treated with a second-line drug regimen 36 . Based on parsimony analysis, the phylogenetic distribution of prpR mutants displays convergent evolution of particular SNPs indicative of positive selection ( Fig. 2a and Supplementary Table 7 ). Although prpR mutations are significantly enriched in drug-resistant isolates, mutations including those identified as convergent also occur in 5% (10/200) of pan-susceptible isolates ( Fig. 2b ), suggesting that they do not directly cause drug resistance in standard culture conditions.
We therefore sought to define the basis of the association between prpR mutations and drug resistance. prpR is a transcription factor that is divergently transcribed from the prpDC operon in M. tuberculosis. The prpD and prpC genes encode proteins that mediate the first two steps in the methylcitrate cycle (MCC), which converts propionyl-CoA into pyruvate ( Fig. 2c ). Following exposure to propionate, or propionyl-CoA generating carbon sources such as cholesterol, which is essential for M. tuberculosis growth in vivo 37 , prpDC is strongly upregulated in a prpR-dependent fashion 38, 39 . Deletion mutants of either prpDC or prpR, which are deficient in MCC activity, are unable to grow in medium containing cholesterol or propionate either as a sole carbon source or as components of mixed carbon sources, perhaps due to accumulation of unmetabolized propionyl-CoA 40 .
To directly assess the functional consequence of the identified prpR mutations, we constructed an isogenic panel of prpR SNP mutants by complementing a prpR deletion in the laboratory strain H37Rv with a chromosomally integrated copy of prpR containing the wild-type sequence, three common point mutations identified by our analysis or an empty vector. In liquid media containing Articles NATuRe MICRobIology acetate and glycerol as carbon sources, all strains grew at similar rates (Fig. 2d ). However, in media containing propionate and glycerol, ΔprpR::vector was strongly attenuated for growth while ΔprpR::D160G and ΔprpR::G361C demonstrated an extended lag phase before resuming growth approximately six days after exposure. In contrast, the deletion mutant complemented with wild-type prpR or E135G grew at the same rate as H37Rv ( Fig. 2e ). Consistent with these observations, prpD upregulation in response to propionate exposure was completely abrogated in the ΔprpR::vector strain and highly attenuated in strains expressing the D160G and G361C variants ( Fig. 2f ). We considered the possibility that the late growth of the D160G and G361C variants reflected the outgrowth Known lineages are marked outside the tree. Sublineages of China strains within L2 and L4 are highlighted with background shadows (names followed as previously described by Zhang et al. 29 ). The tree scale represents mutations per site. c, Genetic associations with isoniazid resistance among 549 strains from China. Each circle represents a gene or intergenic-region in the M. tuberculosis genome. The y axis represents uncorrected phyOverlap P values; genes above the grey line are genome-wide significant with q < 0.05 after correction with the Benjamini-Hochberg procedure. The colours denote loci known to contribute to resistance and the sizes correspond to the number of times mutations were acquired across the data set based on parsimony. d, Comparison of genes identified in our sequence collection (Study A, 549 strains) with those identified using the same method on strain collections from Walker et al. 30 (Study B, 784 strains) and Zhang et al. 29 (Study C, 161 strains). Genes are sorted by significance after performing a meta-analysis of the phyOverlap P values using Fisher's method and correction with the Benjamini-Hochberg procedure. Genes above the grey line are genome-wide significant in the meta-analysis with q < 0.05.
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NATuRe MICRobIology of suppressor mutants; however, when bacteria from propionatecontaining media were recovered in standard 7H9 media and then re-exposed to propionate, they remained sensitive to propionate, exhibiting the same extended lag in growth ( Supplementary Fig. 3 ). Taken together, these data demonstrate that at least a subset of common prpR mutants are hypomorphic for MCC activity and have altered growth characteristics in propionate-containing media.
prpR mutants exhibit conditional drug tolerance in vitro. We then assessed the effect of prpR mutations on both resistance and tolerance to isoniazid, rifampin and the second-line fluoroquinolone ofloxacin. Although propionate supplementation itself unexpectedly increased rifampin resistance in all strains, the antibiotic-dependent inhibition of growth in prpR mutants did not differ from wild-type M. tuberculosis for any drug regardless of the 
NATuRe MICRobIology presence of propionate ( Fig. 3a-c) . To determine the impact of prpR mutations on drug tolerance, we performed time-dependent killing assays on strains after two days of exposure to acetate or propionate, when differences in growth kinetics were apparent. We tagged each prpR variant strain with a unique molecular barcode, allowing us to combine all strains into a single pool. During antibiotic treatment, we then followed the survival of each strain by measuring the total pool of c.f.u. and accounting for the relative abundance of each strain by deep sequencing of the surviving population recovered on drug-free media.
In medium supplemented with acetate, all strains were killed to a similar extent by all antibiotics tested. In contrast, in medium supplemented with propionate, ΔprpR::vector, ΔprpR::D160G and ΔprpR::G361C were significantly more drug tolerant than ΔprpR::WT, showing dramatically increased survival and delayed killing during isoniazid and ofloxacin treatment ( Fig. 3d ). To distinguish between altered killing due to population drug tolerance versus increased persister formation, we estimated the time for a given drug to kill 90% of bacteria. This metric, known as the minimum duration of killing (MDK 90 ), has been proposed as a way of formally discriminating between population-wide drug tolerance and increased persister formation 10 . The MDK 90 for H37Rv and ΔprpR::WT in propionate is 2-3 days in isoniazid and 1-2 days in ofloxacin, while the MDK 90 for ΔprpR::vector, ΔprpR::D160G and 
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ΔprpR::G361C is > 6 days in each case. The prolonged MDK 90 indicates population-wide drug tolerance and is consistent with visual inspection of the curves, where prpR mutants display slower overall killing kinetics rather than a higher plateau of persister cells. Similarly, prpR mutants were also more tolerant of rifampin; however, the survival advantage was more modest, potentially reflecting the dampened killing of even the wild-type strains at this dose of rifampin in propionate. Under our assay conditions, the prpR mutants were eventually killed by high doses of isoniazid and ofloxacin at late time points that largely coincided with resumed growth in the no-drug controls ( Supplementary Fig. 4 ).
To confirm the findings of these competition-based assays, we performed single-strain antibiotic killing assays measuring the survival of a subset of strains at six days post treatment. As in the competition assays, ΔprpR::vector and ΔprpR::G361C had significantly increased survival in isoniazid and ofloxacin treatment in a propionate-dependent manner ( Fig. 3e-g) . Single-strain analysis also demonstrated increased survival of prpR mutants during rifampin treatment.
prpR mutations increase drug tolerance during human macrophage infection. We next measured the effects of the prpR mutations on drug susceptibility during M. tuberculosis infection. Previously published data demonstrated that prpR and prpDC are essential for normal growth of M. tuberculosis in macrophages 38 ; however, the MCC is dispensable for bacterial growth in mice 40 , perhaps as a result of known differences between mouse and human tissues in the availability of vitamin B12 41 , which activates a MCC bypass pathway (Fig. 2c ). Recognizing the limitations of each model, we assessed the effects of the prpR mutations on drug efficacy in mice and in human-derived macrophages. Consistent with published data, the prpR mutants did not have a fitness defect in mice and did not alter drug efficacy ( Supplementary Fig. 5 ). In primary human macrophages in the absence of drug treatment, the prpR mutants had modest but significant decreases in fitness when compared with ΔprpR::WT (Fig. 4a ). Strikingly, however, when infected macrophages were treated with isoniazid, ofloxacin or rifampin, at concentrations far above the minimum inhibitory concentration, the survival of the prpR mutants was significantly greater than that of ΔprpR::WT ( Fig. 4b-d ). Note that ΔprpR::WT was slightly more drug tolerant than H37Rv, probably reflecting incomplete complementation of the prpR deletion. Even the E135G prpR mutation, which had little discernible effect during in vitro functional testing, was modestly but consistently more drug tolerant than ΔprpR::WT in human macrophages treated with isoniazid and rifampin ( Fig. 4b,d ). All of the prpR mutants were similarly more tolerant of all three antibiotics in the human-derived macrophagelike THP-1 cell line ( Fig. 4e ).
prpR tolerance depends on propionyl-CoA intoxication. Although the best-defined role of prpR is regulation of prpC and prpD expression, prpR has been implicated in activation of icl-1, which mediates the conversion of methylisocitrate to succinate and pyruvate in the MCC, and ramB, which is itself a repressor of icl-1 expression in some conditions 42 . prpR has also been proposed to have additional regulatory roles including as a transcriptional repressor of the lipid metabolism transcriptional regulator gene kstR, and the cell cycle regulator gene dnaA, which was independently associated with antibiotic resistance in our meta-analysis ( Fig. 1d ). Like prpC and prpD, icl-1 expression in propionate-containing media was strongly attenuated in the prpR mutants, as was ramB to a lesser extent. By contrast, expression of both kstR and dnaA was unaffected by prpR mutation under these conditions ( Supplementary Fig. 6 ). Thus, the clearest consequence of the prpR mutations is altered expression of MCC components.
We therefore examined whether mutations in genes encoding other steps of the MCC are associated with drug resistance in our cohort. Mutations in prpC, which catalyses the first step of the MCC, are enriched in drug-resistant strains (8/9 prpC mutants are isoniazid resistant, phyOverlap P = 0.03) but because they are less common than prpR mutations, prpC failed to reach significance in the genome-wide screen. Mutations in prpD or icl-1 were not 
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NATuRe MICRobIology associated with drug resistance; however, loss-of-function mutations in icl-1 are lethal when M. tuberculosis is grown in the presence of propionate 43 , and thus mutation of icl-1 may not represent a possible evolutionary path to drug tolerance. Given that prpR mutants exhibit increased drug tolerance only in the presence of propionate or within macrophages, we next hypothesized that accumulation of propionyl-CoA through defective regulation of the MCC, rather than propionate exposure itself, could serve as an environmental response mechanism to slow the bacterial growth rate and thus increase tolerance to mechanistically unrelated drugs targeting growth processes. Previous studies have described growth inhibition due to propionyl-CoA accumulation in MCC mutants and have shown that growth inhibition can be rescued by supplementation with vitamin B12, which allows propionyl-CoA to be metabolized through the B12-dependent methylmalonyl-CoA pathway 44 (Fig. 2c ). Consistent with this hypothesis, B12 supplementation during in vitro growth with propionate rescued the growth defects of the prpR-deficient strains (Fig. 5a,b ) and significantly re-sensitized prpR mutants to isoniazid, rifampin and ofloxacin ( Fig. 5c-f ). Supplementation with vitamin B12 also rescued the fitness defects of prpR mutants in THP-1 cells, while simultaneously re-sensitizing these strains to isoniazid (Fig. 5g,h ), suggesting that propionate stress mediates antibiotic tolerance during macrophage infection as well. Overall, these data suggest that the hypomorphic prpR alleles act as a conditional brake on growth, creating drug tolerance, under conditions when the bacterium metabolizes propionate but cannot access the methylmalonyl-CoA pathway.
Discussion
Bacterial genomic association studies promise to provide unique insights into the key processes driving the progression and treatment response of human TB. In contrast to in vitro bacterial genetic screens, these approaches do not require a priori knowledge of the relevant environmental conditions or altered bacterial phenotypes that contribute to the final phenotypes measured in clinical settings. This represents both a strength and a weakness, as associations capture a wide array of mechanistic drivers that must be carefully dissected.
Here we performed a genome-wide association study with isoniazid resistance, leveraging clinical isolates from the Chinese national survey of drug-resistant TB and cohorts of M. tuberculosis strains collected in China, Europe and Africa. In addition to identifying many known genetic determinants of drug resistance, we define two statistically significant associations with drug resistance, 
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NATuRe MICRobIology prpR and Rv2752c, putatively encoding RNase J, both of which had no known relationship with drug resistance. We validated our approach by defining the mechanistic basis for the association with prpR, a transcriptional regulator of propionate metabolism. Rather than causing drug resistance per se, we demonstrate that common prpR mutations confer multidrug tolerance against several mechanistically unrelated antibiotics.
In the case of prpR, these tolerance mutations have remained unrecognized because the effects of prpR mutations on antibiotic efficacy are not captured in standard drug susceptibility studies, which measure drug resistance, not drug tolerance, and are performed under only one growth condition. Nevertheless, the population-based association of prpR mutations with drug resistance provides a real-world demonstration of the stepping-stone nature of drug tolerance that has been described in E. coli in vitro 21 .
However, from these data, it is difficult to determine which antibiotics might be most affected by prpR mutations in clinical practice. It is possible that, in TB patients, prpR mutations broadly slow bacterial clearance by the first-line regimen. Alternatively, these mutations may have greater effects on the efficacy of certain antibiotics, perhaps because of the in vivo pharmacology of the individual drugs. Moreover, there may be host or disease state factors that influence the impact of prpR mutations perhaps by altering the availability of propionate or vitamin B12. Our in vitro data further suggest that prpR point mutants may be most protective during acute exposure to metabolic stress, and during chronic exposure may eventually resume growth and become re-sensitized to antibiotics, although in mouse models, cholesterol metabolism appears most important during chronic infection 37 . The extent to which M. tuberculosis moves in and out of these metabolic stresses in humans is unknown and could determine the degree of protection. This effect may account for the notable lack of any INDEL or nonsense mutants in prpR across any data set examined as part of our analyses, where mutations providing a balance between tolerance and growth are optimal for fitness during treatment. The extent to which these factors impact the frequency of prpR mutants in the population may also explain the uneven distribution and strength of association with prpR mutants across global data sets.
Regional differences in second-line drug regimens may also contribute to the discordances between the published M. tuberculosis genome-wide association studies. This type of effect can clearly be seen for eis promoter mutations, which are known to cause kanamycin resistance. eis promoter mutations evolved only twice in our Chinese cohort and thus are not significantly associated with any drug resistances. By contrast, these mutations evolved 31 times in the European/African cohort where they were significantly associated with isoniazid resistance without being a causal determinant (Fig. 1d) . Thus, regional differences in second-line drug usage may contribute to different associations, as could geographic differences in public health infrastructure that could impact drug access and quality. In either case, measuring the association with the true phenotype, rather than a correlate, would presumably decrease variability among study groups. Moreover, it is possible that certain mutations may be more common in some mycobacterial lineages or strains due to genetic epistasis 34 , although we observe prpR mutations in both lineage 2 and lineage 4 backgrounds in our data set.
Finally, on the basis of the blunted efficacy of several antibiotics in our study, we hypothesize that prpR mutations may also contribute directly to treatment failure even in the absence of acquired drug resistance. As noted above, prpR mutations are found in 5% of drugsusceptible strains in China and 1-2% in other regions of the world. Other genes identified in this study also contain convergent mutations in drug-susceptible strains; for example, Rv2752c mutations are present in 4% of drug susceptible strains. Testing the hypothesis that these mutations may also contribute directly to treatment failure will require improved clinical end points for genetic association, ideally including metrics such as relapse and failure to convert to diagnostic culture negativity during treatment. While assaying drug tolerance under a range of growth conditions is not feasible in clinical practice, further characterization of these genetic associations will permit the identification of tolerant strains through molecular diagnostics and allow for targeted therapies and monitoring to help prevent the emergence of de novo drug resistances and improve treatment outcomes.
Methods
Strain selection and culture. A national survey of drug-resistant TB was conducted in China in 2007, which collected a total of 3,929 clinical M. tuberculosis isolates from 70 sites of 31 provinces in mainland China 18 . The study was approved by the Tuberculosis Research Ethics Review Committee of the China CDC. Written informed consent was obtained from each participant. Three subsets of the collection were included in the current study based on the following criteria: all MDR strains (defined as isolates that were resistant to at least isoniazid and rifampin); all isoniazid mono-resistant strains (defined as isolates that were resistant to isoniazid but sensitive to all of the other 5 drugs including rifampicin, streptomycin, ethambutol, ofloxacin and kanamycin); 3-5 randomly selected drug-sensitive strains (defined as isolates that were sensitive to all of the six drugs aforementioned) from each of the 70 collection sites. All isolates were cultured on Lowenstein-Jensen slants at 37 °C for 4-6 weeks. Strains that failed in bacterial revival or produced abnormal/mixed colonies were excluded from further analysis. In all, 288 MDR strains, 61 isoniazid mono-resistant strains and 200 drug-sensitive strains were available for follow-up whole-genome sequencing.
Sequencing, alignment and SNP calling. Genomic DNA was extracted from each isolate using standard methods 45 , and was then sequenced on the Illumina GAIIx or HiSeq 2500 platforms, generating single-end reads of 72 base pairs (bp) or 101 bp in length. For each sample, duplicate reads were removed by custom Perl scripts. Further quality control was conducted using the NGSQCToolkit 46 with a cutoff of Q20. Valid reads were then aligned to the reference genome sequence of H37Rv (GenBank accession NC_000962) using the Burrows-Wheeler algorithm as implemented in BWA 47 . SNPs were identified with a minimum depth of 10× and a consensus quality score of 50 using SAMtools 48 . For the publicly available complete/draft genomes involved in our phylogenetic analysis (Supplementary  Table 2 ), the wgsim program from the SAMtools package was used to generate three million 72-bp single reads for each to generate an ~50× depth of simulated sequencing data for each genome and SNPs were identified as above. SNPs located within repetitive regions, including transposases, PE/PPE genes, prophages and exact sequence repeats of the H37Rv genome previously proposed 49 or identified by RepeatMasker (http://www.repeatmasker.org/) or PhageFinder 50 , were excluded. Mixed base calls were considered valid only if the numbers of the most abundant (n1) and the second most abundant (n2) nucleotides at each SNP in each strain satisfied the criterion n1/n2 ≧ 5. The detailed workflow of the SNP-calling procedure of data sets for follow-up analysis is given in Supplementary Fig. 7 .
Phylogenetic analysis.
A concatenated superset of SNPs relative to H37Rv was generated across all 549 sequenced strains and 130 published M. tuberculosis genomes (Supplementary Table 2 ). SNP sites with missing data in over 5% of the strains within the data set were removed. To avoid the potential effects of homoplasy of drug-resistance-associated mutations in phylogeny, SNPs located in known drug-resistance-related genes available from TBDReaMDB 51 were further excluded from the data set for phylogenetic tree construction ( Supplementary  Fig. 7) . A strain of Mycobacterium canetti was included as an outgroup (GenBank accession NC_015848). The refined SNP set was used to construct the maximumlikelihood phylogeny using RAxML 52 under the GTRgamma substitution model. The reliability of each node was tested via a bootstrap analysis on 100 resampled data sets. The iTOL server 53 and MEGA5 54 software were employed for the manipulation and presentation of the phylogenetic trees. To define clusters, we first employed a threshold of 100 SNPs among isolates based on molecular clock estimates of ~0.5 SNPs accumulating per strain per year where larger distances would place the most recent common ancestor of a set of isolates before the widespread use of isoniazid. We also assessed the isoniazid-resistance-determining SNP present within each cluster to discriminate true isoniazid-resistant clusters from closely related isolates with distinct resistance-causing mutations.
Drug-resistance associations. Genomic associations were performed using a method similar to that of Farhat et al. 27 that we refer to as phyOverlap. We performed maximum parsimony ancestral sequence reconstruction to determine the state of each SNP residue at the common ancestor of our strain collection using the Mesquite software package (http://mesquiteproject.org/). In cases where the ancestral sequence could not be unambiguously determined, we excluded the site from further analysis. Each isolate was then scored as ancestral or derived for a given SNP locus. Isolates with ambiguous base calls were considered ancestral for this calculation to minimize the potential of error driving associations with drug Articles NATuRe MICRobIology resistance. The overlap with drug resistance was scored by dividing the number of isolates containing a derived allele that also were resistant to isoniazid by the total number of isolates with a derived allele at a given SNP locus. To generate a gene-wide score, we excluded synonymous SNPs and averaged the individual SNP scores, weighting the scores by the number of times derived alleles evolved across the phylogenetic tree. The number of times a site mutated across the tree was calculated as the parsimony score at each SNP position using the Fitch algorithm as implemented in the R package phangorn 55 . This was performed with mixed bases treated as missing data so that low-quality base calls would not appear highly convergent.
Significance testing was performed by redistributing the mutation events in each SNP in each gene randomly across the phylogenetic tree, with the probability of a mutation occurring on any branch proportional to the branch length and all offspring of a branch being assigned the derived allele for calculation of the permuted overlap score. The gene-wide score was then recalculated and compared with the actual value. This process was repeated 50,000 times to derive an empirical P value. For all statistical calculations, associations that achieved a P value of 0 were considered < 2 × 10 −5 . False-discovery-rate q values were then calculated to account for multiple-hypothesis testing using the Benjamini-Hochberg procedure 56 .
Analysis of data from Zhang et al. 29 and Walker et al. 30 was performed using the same SNP calling and association pipeline described above ( Supplementary  Fig. 7 ). We utilized a subset of 784 isolates from Walker et al. 30 including 369 drug-sensitive isolates, 34 isoniazid mono-resistant isolates, and 381 MDR isolates that had additional drug resistance in some cases (Supplementary Table 5 ). Metaanalysis P values were calculated using Fisher's method.
Analysis of the data from Casali et al. 34 , Guerra-Assunção et al. 33 and Holt et al. 35 was performed with a slightly modified workflow to accommodate the larger data sets. Isolates not achieving 90% coverage of the H37Rv genome at 10× depth were excluded from analysis. SNP calling was performed with the HaplotypeCaller tool Genome Analysis Toolkit version 3.6 57 . Sites with less than 10× coverage or < 90% majority base call were treated as missing data. As above, repetitive regions, known DR-associated regions, and sites with < 95% confident calls among strains were excluded from further analysis. Phylogeny reconstruction was performed using FastTree 58 using the GTR model and rooted at the midpoint. Strains were considered isoniazid resistant if they had any mutation within katG excluding the known lineage-associated R463L variant or contained a mutation in the fabG1-inhA promoter region.
Growth conditions and strain construction. M. tuberculosis strains were maintained in 7H9 media comprised of Middlebrook 7H9 salts supplemented with 0.2% glycerol, 10% OADC and 0.05% Tween 80. The acetate and propionate exposures were performed in 7H12 media comprised of Middlebrook 7H9 salts, 0.1% casamino acids, 0.2% glycerol and 0.05% tyloxapol, and then supplemented with 0.02% of either sodium acetate or sodium propionate. Vitamin B12 was supplemented as cobalamin at a concentration of 10 μ g ml −1 where indicated. Outgrowth of bacteria on solid media was performed on 7H10 agar supplemented with 0.5% glycerol, 10% OADC and 0.05% Tween 80.
The ΔprpR strain was constructed as described in an earlier study 38 by Griffin et al. prpR-complemented strains were constructed by integration of a kanamycin-resistant, prpR-bearing plasmid at the L5 phage integration site. prpR expression was driven by the native promoter sequence spanning 95 bases upstream of the annotated prpR sequence. Both the wild-type strain and ΔprpR::vector had similar plasmids lacking prpR introduced into the genome. Each prpR variant and empty vector was tagged with a unique DNA barcode, isolated from the prpR promoter sequence by two copies of the rrnB transcriptional terminator, to reduce the likelihood of any tag effect on prpR expression.
Growth curves and prpR/prpD expression analysis.
For measurement of growth, the indicated strains were grown into mid-log phase in 7H9 media, spun down and resuspended to an OD 600 nm of 0.01 in 7H12 media with the indicated short-chain fatty acid. OD 600 nm was measured daily. The data are representative of three biological replicates. Regrowth of propionate-exposed strains displayed in Supplementary Fig. 3 was performed after recovery in 7H9 media for seven days. For expression analysis, the indicated strains were grown into mid-log phase in 7H9 media, spun down and resuspended to an OD 600 nm of 0.1 in 7H12 media with the indicated short-chain fatty acid. After two days of growth, cultures were spun down, resuspended in 1 ml Trizol reagent and disrupted by bead beating. Chloroform was added to 25% of the total volume and then RNA was extracted using the Direct-zol miniprep kit (Zymo Research). Eight hundred nanograms of total RNA was used as a template for cDNA synthesis with random hexamers using SuperScript IV reverse transcriptase (ThermoFisher Scientific). Transcript abundance was measured by qPCR and normalized with sigA expression with the following primers: prpD 5ʹ -TGACTTTCACGACACGTTTCTGGC-3ʹ and 5ʹ -TGTGGATCTCATAGGCGGTTACCA-3ʹ ; prpR 5ʹ -ATGTCAACCAGTTGGAGAATGA-3ʹ and 5ʹ -CGGAATCCGAGGAGAAATACTG-3ʹ ; sigA 5ʹ -CAAGTTCTCCACCTACGCTAC-3ʹ and 5ʹ -GTTGATCACCTCGACCATGT-3ʹ ; dnaA 5ʹ -TACACGCGGCAGGCAACT-3ʹ and 5ʹ -GGAGACATATTTGACCCGCATT-3ʹ ; ramB 5ʹ -CCTGCCCGCTGTGGAA-3ʹ and 5ʹ -GGCGATTTGCACCAAGATCT-3ʹ ; icl-1 5ʹ -CAGCACATCCGCACTTTGAC-3ʹ and 5ʹ -ATCACCACCGTGGGAACATC-3ʹ ; kstR 5ʹ -CCAGCGGCTGAACTTTATGG-3ʹ and 5ʹ -TGTCATGGCCTCGGTGAGTA-3ʹ .
Mean relative expression across three biological replicates was compared and P values were determined using Tukey's honestly significant difference post-hoc test after analysis of variance (ANOVA).
Antibiotic-susceptibility testing. Minimum inhibitory concentrations were measured using the Alamar Blue reduction assay. Strains were grown to mid-log phase, spun down and resuspended in 7H12 media with the indicated short-chain fatty acid. After two days of growth, each strain was diluted to OD 600 nm 0.0015 in 200 μ l of the appropriate media with antibiotics at the indicated concentrations. Twenty microlitres of Alamar Blue reagent was added at four days post drug exposure, and reduction was measured by OD 570 nm at eight days post drug exposure. The percentage of growth was normalized for each strain in each growth condition by subtracting the OD 570 nm of a no-cell well and scaling by the reduction measurement of a no-drug control. The minimum inhibitory concentration data are representative of two independent replicates.
A library containing H37Rv and all prpR mutants described above was constructed by mixing all strains at equal density. Several aliquots were then frozen to ensure the library would remain consistent between experiments. Antibiotic tolerance was measured using time-dependent killing assays. The library was grown to mid-log phase, spun down and resuspended in 7H12 media with the indicated short-chain fatty acid to OD 600nm 0.05 in triplicate for each condition. After two days of growth, the colony-forming units (c.f.u.) per millilitre were measured by plating serial dilutions onto solid media and enumerating colonies after 21 days of growth. After the initial c.f.u. measurement, antibiotics were applied in the indicated concentrations. c.f.u. determination was performed for each replicate every two days for the next six days. To measure the relative abundance of each strain during treatment, a bulk sample representing > 1,000 c.f.u. was plated onto drug-free media at each time point. After 21 days of growth on solid media, gDNA was extracted from the entire resulting biomass. Amplicon sequencing libraries spanning the variable region of each unique molecular barcode were generated using PCR primers binding to regions common among all vectors as previously described 59 . During this PCR, random nonamers were incorporated into the sequence to allow for the accurate determination of input templates. The abundance of each barcode was then measured by deep sequencing on the Illumina MiSeq platform. Each library represented at least 40,000 unique combinations of barcodes and template counters. The fraction of the c.f.u. in each replicate/condition attributable to each strain was calculated by dividing the total c.f.u. by the representation of each strain as determined by sequencing. To calculate fraction survival, the c.f.u. at each point was divided by the measured starting c.f.u. that was normalized to 1. To test for differences in the fraction of surviving bacteria, survival fractions were log transformed and the differences among mean survivals were compared using Tukey's honestly significant difference post-hoc test within time points after two-way ANOVA.
Single-strain survival was analysed in a similar fashion. Two days of shortchain fatty acid exposure was performed before antibiotic treatment, as described above. c.f.u. was measured immediately before antibiotic addition, and after six days of antibiotic exposure, the ending c.f.u. was quantified and the fraction of cells surviving was calculated. The data for each condition are representative of three independent biological replicates.
Mouse and macrophage infection and competition measurement.
All mouse experiments were approved by the Harvard University Institutional Animal Care and Use Committee as complying with ethical regulations. The programme and facility is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International and the Office of Laboratory Animal Welfare assurance number is A3431-01. Six-to eight-week-old female C57BL/6J mice were obtained from Jackson Laboratories. Infection was initiated by tailvein injection of the prpR library at 1 × 10 5 c.f.u. in a 100 μ l injection. On day 1 post infection, 3 mice were euthanized, spleens were collected and homogenized in phosphate-buffered saline, and bacterial burden was determined by plating serial dilutions on 7H10 agar. Concurrently with c.f.u. determination, additional homogenate was frozen in 10% glycerol at − 80 °C. Colonies were counted after 21 days of incubation at 37 °C. At 14 days post infection, an additional 5 mice were euthanized and the remaining mice were administered antibiotics or served as no-drug controls (n = 5 per time point per treatment). Mice were treated by ad libitum administration of drugs through their drinking water containing either isoniazid at 0.1 g l −1 , rifampin at 0.1 g l −1 or moxifloxacin at 0.4 g l −1 . The sample size was selected on the basis of the initial validation of the strain tagging and pooling system described by Blumenthal et al. 60 where groups of 4-5 mice were sufficient to identify roughly 10-fold changes in in vivo abundance of mutants. After c.f.u. determination, bacterial colonies were scraped from the plates and gDNA was extracted. In cases where < 500 colonies were sampled, additional frozen material was plated to increase the sample size of recovered bacteria. Sequencing library preparation was performed as described above. Relative abundance was determined by dividing the number of reads from each molecular barcode by the number of reads from the molecular barcode corresponding to ΔprpR::WT, Articles NATuRe MICRobIology and the starting relative abundance for each strain was set to 1 by dividing each value by the average abundance of a strain in the inoculum as measured from libraries plated on solid media on the same day as initiation of infection. There was no randomization in this study because there were no features for which randomization was deemed appropriate. Similarly, blinding was not performed in these experiments. The measurements of c.f.u. and representation of strains in competition assays do not require researcher-based judgements and therefore we deemed blinding unnecessary.
Human blood components (buffy coats) for macrophage experiments were procured through Blood Transfusion Services at Massachusetts General Hospital (MGH) for in vitro research by Investigators at the Ragon Institute of MGH, MIT and Harvard. These specimens were collected from donations for clinical use and only excess blood or blood products that are not needed are then processed for research purposes. The specimens supplied for these purposes are not identifiable. Donors in the Blood Transfusion Services at MGH sign a Donor Consent within a Registration Form that includes the following sentence, 'I give permission for my blood to be used for transfusion to patients or for research' . This protocol was approved by the MGH Human Research Committee.
Peripheral blood mononuclear cells were isolated by Ficoll gradient separation. CD-14-positive cells were then positively selected using the EasySep Human CD14 Positive Selection Kit (Stemcell Technologies). Isolated CD-14-positive cells were matured for 6 days incubated on ultralow-attachment plates at 37 °C in 5% CO 2 in RPMI supplemented with 2 mM l-glutamine, 10 mM Hepes and 10% fetal bovine serum. After 6 days, cells were collected and transferred to 12-well tissue culturetreated dishes at a density of 500,000 cells per well and allowed to rest overnight. The prpR mutant library described above was then used to initiate infections. The library was spun down, resuspended in cell culture media, passed through a 5 μ m filter and diluted to 2 million cells per millilitre. A portion of this library was plated in triplicate to allow for measurement of the relative abundance of each strain in the input library. Five hundred microlitres of prepared library was then applied to each well of macrophages and infection was allowed to proceed for 3 h. The infected macrophages were then washed three times with RPMI and covered with culture media. Bacteria were collected from three wells at one day post infection to measure the abundance of each strain in the macrophages directly before antibiotic addition. Antibiotic treatment was then initiated by removing half of the medium and replacing it with a 2× antibiotic solution to achieve a final concentration of either no drug, isoniazid at 3 μ g ml −1 , ofloxacin at 2.5 μ g ml −1 or rifampin at 5 μ g ml −1 . At each time point, bacteria were recovered from the macrophages by removing culture media and adding 0.1% Triton 100 in water and then plating on solid media for 21 days. Each treatment was performed in triplicate wells. The fitness of each strain was compared with ΔprpR::WT by one-way t-test against the normalized ΔprpR::WT of 1.0 and multiple-test correction was performed for each treatment using false-discovery-rate correction.
THP-1 cells were obtained from ATCC. Cells were not authenticated or tested for mycoplasma contamination. THP-1 infection was largely identical to infection of human peripheral blood mononuclear cell-derived macrophages except: THP-1 cells were matured by addition of PMA at 50 ng ml −1 final concentration for 24 h, followed by removal of PMA for 16-24 h before infection with the tagged strain library at a multiplicity of infection of 1.
Reporting Summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this article.
Code availability. The code used to perform statistical testing of the phylogenetic overlap between mutations and antibiotic resistance (phyOverlap) is available for download at https://github.com/nathan-d-hicks/phyOverlap. This also contains all of the input files used to generate Fig. 1c including the phylogenetic tree and SNP calls.
Data availability. Sequencing reads have been submitted to the NCBI Sequence
Read Archive (SRA) under accession PRJNA268900. A complete list of the TB strains analysed in this study together with phenotypic and sequencing information is given in Supplementary Table 1 . Strains added for phylogenetic reference in Fig. 1b A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Our web collection on statistics for biologists may be useful.
Software and code
Policy information about availability of computer code
Data collection
Genomes were sequenced on the Illumina GAIIx or HiSeq 2500 platforms, generating single end reads of 72 bp or 101 bp in length.
Data analysis
The code used to analyze the data in this study include commercially available and custom softwares as described in detail in the methods. We have described it briefly below.
For each sample duplicate reads were removed by custom Perl scripts. Further quality control was conducted using the NGSQCToolkit with a cutoff of Q20. Valid reads were then aligned to the reference genome sequence of H37Rv (GenBank accession NC_000962) using the Burrows-Wheeler algorithm as implemented in BWA. SNPs were identified with a minimum depth of 10X and a consensus quality score of 50 using SAMtools. SNPs located within repetitive regions, including transposases, PE/PPE genes, prophages and exact sequence repeats of the H37Rv genome previously proposed or identified by RepeatMasker (http://www.repeatmasker.org/) or PhageFinder 40, were excluded. Mixed base calls were considered valid only if the numbers of the most abundant (n1) and the second most abundant (n2) nucleotides at each SNP in each strain satisfied the criteria n1/n2 5. The detailed workflow of the SNP-calling procedure of datasets for follow-up analysis is given in Supplementary Figure 7 .
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maximum parsimony ancestral sequence reconstruction to determine the state of each SNP residue at the common ancestor of our strain collection using the Mesquite software package (http://mesquiteproject.org/). In cases where the ancestral sequence could not be unambiguously determined, we excluded the site from further analysis. Each isolate was then scored as ancestral or derived for a given SNP locus. Isolates with ambiguous base calls were considered ancestral for this calculation to minimize the potential of error driving associations with drug resistance. The overlap with drug resistance was scored by dividing the number of isolates containing a derived allele which also were resistant to isoniazid by the total number of isolates with a derived allele at a given SNP locus. To generate a genewide score, we excluded synonymous SNPs and averaged the individual SNP scores, weighting the scores by the number of times derived alleles evolved across the phylogenetic tree. The number of times a site mutated across the tree was calculated as the parsimony score at each SNP position using the Fitch algorithm as implemented in the R package phangorn. This was performed with mixed bases treated as missing data so that low quality base-calls would not appear highly convergent. Significance testing was performed by redistributing the mutation events in each SNP in each gene randomly across the phylogenetic tree, with the probability of a mutation occurring on any branch proportional to the branch length and all offspring of a branch being assigned the derived allele for calculation of the permuted overlap score. The gene-wide score was then recalculated and compared with the actual value. This process was repeated 50,000 times to derive an empirical p-value. For all statistical calculations, associations which achieved a p-value of 0 were considered <2x10-5. False discovery rate q-values were then calculated to account for multiple hypothesis testing using the Benjamini-Hochberg procedure.
Scripts for this method are available online at: https://github.com/nathan-d-hicks/phyOverlap For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data
Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability Sequencing reads have been submitted to the NCBI Sequence Read Archive (SRA) under accession PRJNA268900. A complete list of the new TB strains analyzed in this study together with phenotypic and sequencing information is given in Supplementary Table 1 . The accession numbers for previously sequenced strains used in Figures 1B, 1D , and Table 1 are available at in Supplementary Table 2 and Supplementary Table 8 .
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Study design
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Sample size
Sample size calculations are relevant for experiments shown in Figures 2-5 . The growth curves and expression data presented in the manuscript consist of three biological replicates ( Figure 2 ). We used three biologically independent replicates for in vitro killing assays ( Figures  3, 4 , 5) which our preliminary data indicated would be sufficient to measure 2-fold or greater changes in bacterial numbers. Mouse experiments included 5 mice per group which was sufficient to identify roughly 10-fold changes in in vivo abundance of mutants in previously published experiments.
Data exclusions We excluded three datapoints in the entire in the entire study as described below. Figure 3D : A single datapoint was excluded each from the ofloxacin acetate data on day 2 and propionate day 2 due to contamination of the CFU plate. A single datapoint was excluded from the high-dose INH Day 6 propionate in figure 3D where the prpR WT complement had substantially lower reads than in the two other replicates (while true WT H37Rv was unaffected). This exclusion weakened the statistical significance reported at this timepoint, rather than increasing the magnitude of the effect.
Supplemental Figure 5 : RIF Day 57 only has 4 mice because one spleen was contaminated during extraction.
Replication
We have indicated the number of times experiment was independently performed as described below and in the figure legends. The growth curves shown in figure 2 were performed three times, each with three replicates, and yielded similar results. The MIC assays presented in Figure 3 a-c were performed 3 times for the prpR complement and deletion strain and in all cases we did not see prpR dependent antibiotic protection. The library format antibiotic killing in figure 3D was performed once, and then the propionate mediated protection of strains was confirmed in the single strain CFU assays presented in figures 3e-g, which were repeated >3 times. In all cases the prpR mutants displayed
